A 5-year surveillance study on antimicrobial resistance of Acinetobacter baumannii clinical isolates from a tertiary Greek hospital

Infection and Chemotherapy

Volumn 48, Issue 3, 2016, Pages 190-198

  Maraki, Sofia ^a   Mantadakis, Elpis ^b   Mavromanolaki, Viktoria Eirini ^c   Kofteridis, Diamantis P ^c   Samonis, George ^c  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Acinetobacter baumannii; Antimicrobial susceptibilities; Colistin; Multidrug resistance; Tigecycline

Indexed keywords

AMIKACIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TETRACYCLINE; TICARCILLIN; TIGECYCLINE; TIMENTIN; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CRITICALLY ILL PATIENT; GREECE; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; SURGICAL WARD; TERTIARY CARE CENTER;

EID: 84992206071     PISSN: 20932340     EISSN: 20926448     Source Type: Journal    
DOI: 10.3947/ic.2016.48.3.190     Document Type: Article

References (33)

1. Kaye KS, Pogue JM. Infections caused by resistant gram-negative bacteria: epidemiology and management. Pharmacotherapy 2015;35:949-62.
2. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008;46:1254-63.
3. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 (Suppl 2):S49-56.
4. Liu WL, Liang HW, Lee MF, Lin HL, Lin YH, Chen CC, Chang PC, Lai CC, Chuang YC, Tang HJ. The impact of inadequate terminal disinfection on an outbreak of imipenem-resistant Acinetobacter baumannii in an intensive care unit. PLoS One 2014;9:e107975.
5. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008;13.pii:19045.
6. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-8.
7. Rodr�guez-Ba�o J, Pascual A, G�lvez J, Muniain MA, R�os MJ, Mart�nez-Mart�nez L, P�rez-Cano R, Perea EJ. [Acinetobacter baumannii bacteremia: clinical and prognostic features]. Enferm Infecc Microbiol Clin 2003;21:242-7.
8. Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, Shin SY, Ko KS, Peck KR, Lee NY. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007;59:525-30.
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. Wayne, Pa: CLSI; 2014.
10. Food and Drug Administration (FDA). Prescribing information for tygacil (tigecycline); 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s021lbl.pdf . Accessed 27 May 2016.
11. Spiliopoulou A, Jelastopulu E, Vamvakopoulou S, Bartzavali C, Kolonitsiou F, Anastassiou ED, Christofidou M. In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period. J Chemother 2015;27:266-70.
12. Meletis G, Oustas E, Botziori C, Kakasi E, Koteli A. Containment of carbapenem resistance rates of Klebsiella pneumoniae and Acinetobacter baumannii in a Greek hospital with a concomitant increase in colistin, gentamicin and tigecycline resistance. New Microbiol 2015;38:417-21.
13. Arvaniti K, Lathyris D, Ruimy R, Haidich AB, Koulourida V, Nikolaidis P, Matamis D, Miyakis S. The importance of colonization pressure in multiresistant Acinetobacter baumannii acquisition in a Greek intensive care unit. Crit Care 2012;16:R102.
14. Katsaragakis S, Markogiannakis H, Samara E, Pachylaki N, Theodoraki EM, Xanthaki A, Toutouza M, Toutouzas KG, Theodorou D. Predictors of mortality of Acinetobacter baumannii infections: A 2-year prospective study in a Greek surgical intensive care unit. Am J Infect Control 2010;38:631-5.
15. Falagas ME, Mourtzoukou EG, Polemis M, Vatopoulos AC; Greek System for Surveillance of Antimicrobial Resistance. Trends in antimicrobial resistance of Acinetobacter baumannii clinical isolates from hospitalised patients in Greece and treatment implications. Clin Microbiol Infect 2007;13:816-9.
16. Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE, Castanheira M. Resistance surveillance program report for selected European nations (2011). Diagn Microbiol Infect Dis 2014;78:429-36.
17. Giannouli M, Tomasone F, Agodi A, Vahaboglu H, Daoud Z, Triassi M, Tsakris A, Zarrilli R. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii strains in intensive care units of multiple Mediterranean hospitals. J Antimicrob Chemother 2009;63:828-30.
18. Gogou V, Pournaras S, Giannouli M, Voulgari E, Piperaki ET, Zarrilli R, Tsakris A. Evolution of multidrug-resistant Acinetobacter baumannii clonal lineages: a 10 year study in Greece (2000-09). J Antimicrob Chemother 2011;66:2767-72.
19. Jellison TK, Mckinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy 2001;21:142-8.
20. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008;61:1369-75.
21. Beno P, Krcmery V, Demitrovicova A. Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin. Clin Microbiol Infect 2006;12:497-8.
22. Zilberberg MD, Kollef MH, Shorr AF. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study. J Hosp Med 2016;11:21-6.
23. Falagas ME, Vardakas KZ, Roussos NS. Trimethoprim/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence. Int J Antimicrob Agents 2015;46:231-41.
24. Gallagher JC, Rouse HM. Tigecycline for the treatment of Acinetobacter infections: a case series. Ann Pharmacother 2008;42:1188-94.
25. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008;46:567-70.
26. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Mcrobiol Infect 2005; 11:115-21.
27. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D, Michalopoulos A. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010;35:194-9.
28. Souli M, Kontopidou FV, Koratzanis E, Antoniadou A, Giannitsioti E, Evangelopoulou P, Kannavaki S, Giamarellou H. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006;50:3166-9.
29. Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, Samonis G, Falagas ME. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 2008;36:807-11.
30. Tsioutis C, Bathoorn E, Scoulica E, Rossen JW, Bolikas E, Kioulpalis A, Kassimati A, Friedrich AW, Gikas A. Application of international guidelines for the control of a nosocomial outbreak: The example of an outbreak due to pandrug-resistant Acinetobacter baumannii. Twenty-sixth European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, 9-12 April, 2016.
31. Fukuta Y, Muder RR, Agha ME, Clarke LG, Wagener MM, Hensler AM, Doi Y. Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. Am J Infect Control 2013;41:1249-52.
32. Liu Q, Li W, Du X, Li W, Zhong T, Tang Y, Feng Y, Tao C, Xie Y. Risk and prognostic factors for multidrug-resistant Acinetobacter baumannii complex bacteremia: a retrospective study in a tertiary hospital of West China. PLoS One 2015;10:e0130701.
33. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81.